Replies to post #282437 on Avid Bioservices Inc (CDMO)

[nh]

Thanks very much, cjgaddy. EOM

[cjgaddy]

Pipeline Chart on website upd. 1-17-17: AZN entry changed (since 10-13-16 ASM Pipeline chart) from “Mult. Solid Tumors: Combo with durvalumab(anti-PD-L1) + Chemo” to “Mult. Solid Tumors: Combo with durvalumab(anti-PD-L1)”. Ie, “+ Chemo” dropped.

http://www.peregrineinc.com/pipeline/overview.html


- - - - - - - - -
10-13-16 Peregrine's ASM: ATTENDEE Reports & Link to CEO Steve King's 35min/45slide webcast: http://tinyurl.com/jx7ouay

[swg_tdr]

CJ, THOSE BIOMARKERS - interesting $$$....

Garnick shared a story about an early biomarker at Genentech with us that very few people know. Herceptin failed its first trials but one scientist identified the HER2 mutation and saw how many with HER2 lived longer. So they ran another trial which also failed. Garnick and his peers didn't believe in it but one other guy, identified a biomarker that correlated with the ones who lived, and talked them into spending another $60mm on one more trial. Since then Herceptin has save 1000's of lives and earned $Billions of dollars. He believes in the value of biomarkers and he has been driving it for us.

And that was HUGE, extending progression-free for advanced (first-line) but stage 4 by 5 to 8 months (( actually in one case 50% shrinkage, other case the Onco mentioned extended life by 10 years and was still counting) and all those Billion $s ofF only 12% to 15% of lung cancer patients who have this biomarker

Our good responders in the SUNRISE were about 40% of all the subjects if I recall correctly. BIG BUCKS?

thanks CJ for your keeping is current.
N